# US 7,465,444 B2 · Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,465,444 B2
- Document ID: US7465444B2
- Status: Granted
- Kind: B2
- Application number: 10/472,743
- Filed: 2002-02-18
- Published: 2004-07-08
- Granted: 2008-12-16
- Earliest claimed: 2002-02-18
- Assignees: Japan Tobacco Inc.
- Inventors: Mamoru Watanabe
- Web page: https://patentgrep.com/patent/US7465444B2

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and such)), and exhibit a significant therapeutic effect against inflammatory bowel diseases.

## Claims

### Claim 1

A method of suppressing or treating an inflammatory bowel disease in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) an antibody or a portion thereof that binds to human AILIM and inhibits proliferation of an AILIM-expressing cell or production of interferon-gamma or interleukin-4 by an AILIM-expressing cell, and (b) a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antibody or portion thereof induces cell death of an AILIM-expressing cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein said inflammatory bowel disease is colitis.

### Claim 4 (depends on 1)

The method of claim 1, wherein said inflammatory bowel disease is Crohn's disease.

### Claim 5 (depends on 2)

The method of claim 2, wherein said inflammatory bowel disease is colitis.

### Claim 6 (depends on 2)

The method of claim 2, wherein said inflammatory bowel disease is Crohn's disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody or portion thereof is a monoclonal antibody.

### Claim 8 (depends on 7)

The method of claim 7, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antibody or portion thereof is an F(ab′)2fragment, an Fab′ fragment, an Fab fragment, an Fv fragment, or a single domain antibody.

### Claim 10 (depends on 2)

The method of claim 2, wherein the antibody or portion thereof is a monoclonal antibody.

### Claim 11 (depends on 10)

The method of claim 10, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

### Claim 12 (depends on 2)

The method of claim 2, wherein the antibody or portion thereof is an F(ab′)2fragment, an Fab′ fragment, an Fab fragment, an Fv fragment, or a single domain antibody.

### Claim 13 (depends on 3)

The method of claim 3, wherein the antibody or portion thereof is a monoclonal antibody.

### Claim 14 (depends on 13)

The method of claim 13, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

### Claim 15 (depends on 3)

The method of claim 3, wherein the antibody or portion thereof is an F(ab′)2 fragment, an Fab′ fragment, an Fab fragment, an Fv fragment, or a single domain antibody.

### Claim 16 (depends on 4)

The method of claim 4, wherein the antibody or portion thereof is a monoclonal antibody.

### Claim 17 (depends on 16)

The method of claim 16, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

### Claim 18 (depends on 4)

The method of claim 4, wherein the antibody or portion thereof is an F(ab′)2 fragment, an Fab′ fragment, an Fab fragment, an Fv fragment, or a single domain antibody.

### Claim 19 (depends on 5)

The method of claim 5, wherein the antibody or portion thereof is a monoclonal antibody.

### Claim 20 (depends on 19)

The method of claim 19, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

### Claim 21 (depends on 5)

The method of claim 5, wherein the antibody or portion thereof is an F(ab′)2 fragment, an Fab′ fragment, an Fab fragment, an Fv fragment, or a single domain antibody.

### Claim 22 (depends on 6)

The method of claim 6, wherein the antibody or portion thereof is a monoclonal antibody.

### Claim 23 (depends on 22)

The method of claim 22, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

### Claim 24 (depends on 6)

The method of claim 6, wherein the antibody or portion thereof is an F(ab′)2 fragment, an Fab′ fragment, an Fab fragment, an Fv fragment, or a single domain antibody.